Interaction Checker

Époétine alfa : interactions médicamenteuses

Époétine alfa (Epogen, Procrit, Retacrit) présente 249 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 1 de niveau majeur, 89 de niveau modéré, 159 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (1)

  • AlcoolAlcoolMajeure

    …erythropoietin protein drugs [see Warnings and Precautions ( 5.6 )] Serious allergic reactions to Epogen [see Warnings and Precautions ( 5.7 )] Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in: Neonates, infants, pregnant women, and lactating women [see Warnings and Precautions ( 5.9 ), Use in Specific Populations ( 8.1 , 8.2 , 8.4 )] . (notice Époétine alfa, Contre-indications)

Interactions modérées (89)

  • AcébutololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • AténololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • BétaxololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • BisoprololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • CarvédilolbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Clonidineagoniste alpha-adrénergiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Diltiazeminhibiteur calciqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Dinitrate d'isosorbide et hydralazinedérivé nitréModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • DoxazosinealphabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • ÉnoxaparineanticoagulantModérée

    Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (notice Époétine alfa, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Furosémidediurétique de l'anseModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • HéparineanticoagulantModérée

    Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (notice Époétine alfa, Mises en garde et précautions)

  • HydralazinevasodilatateurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • LabétalolbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • MéthyldopaantihypertenseurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • MétoprololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • MinoxidilvasodilatateurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • NadololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • NébivololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Nitroprussiate de sodiumvasodilatateurModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • PhénoxybenzaminealphabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • PindololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • PrazosinealphabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • PropranololbêtabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • TizanidinemyorelaxantModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Torasémidediurétique de l'anseModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueModérée

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (notice Époétine alfa, Mises en garde et précautions)

Mentions mineures (159)

  • Acide valproïqueanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • AlprazolambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Amitriptylineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Amoxapineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • AripiprazoleantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • AsénapineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • AzélastineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Azélastine et fluticasoneantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • BaclofènemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Belladone et opiumopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • BrexpiprazoleantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • BrivaracétamanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Bromphéniramine, pseudoéphédrine et dextrométhorphaneantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • BuprénorphineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Buprénorphine et naloxoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Butalbital et paracétamolbarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Butalbital, aspirine et caféinebarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Butalbital, aspirine, caféine et codéinebarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Butalbital, paracétamol et caféinebarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Butalbital, paracétamol, caféine et codéinebarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ButorphanolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Cannabidiol (sur ordonnance)anticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CarbamazépineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CarbinoxamineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CariprazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CarisoprodolmyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CénobamateanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ChlordiazépoxidebenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Chlordiazépoxide et clidiniumbenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ChlorphénamineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ChlorpromazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ChlorzoxazonemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ClémastineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ClobazambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Clomipramineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ClonazépambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ClorazépatebenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ClozapineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CodéineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CyclobenzaprinemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • CyproheptadineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DantrolènemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Daridorexantsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Desfluraneanesthésique généralMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Désipramineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DexchlorphéniramineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Dexmédétomidineagoniste alpha-adrénergiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DiazépambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DimenhydrinateantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DiphénhydramineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Divalproate de sodium (valproate)anticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Doxépineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DoxylamineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Doxylamine et pyridoxineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • DronabinolcannabinoïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Dropéridolantagoniste de la dopamineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • EslicarbazépineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • EstazolambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Eszopiclonesédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ÉthosuximideanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Étomidateanesthésique généralMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • FelbamateanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • FentanylopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Flibansérinedépresseur du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • FluphénazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • FosphénytoïneanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • GabapentineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • HalopéridolantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • HydrocodoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Hydrocodone et chlorphénamineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Hydrocodone et homatropineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Hydrocodone et ibuprofèneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Hydrocodone et paracétamolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • HydromorphoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • HydroxyzineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • IlopéridoneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Imipramineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Isofluraneanesthésique généralMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Kétaminedépresseur du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LacosamideanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Lemborexantsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LévétiracétamanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LévorphanolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LorazépambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LoxapineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LumatépéroneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • LurasidoneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MéclozineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Méprobamatedépresseur du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MésuximideanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MétaxalonemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MéthadoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MéthocarbamolmyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MéthohexitalbarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Métoclopramideantagoniste de la dopamineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MidazolambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MirtazapineantidépresseurMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • MorphineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • NalbuphineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Nortriptylineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OlanzapineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Olanzapine et fluoxétineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OlicéridineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OrphénadrinemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Orphénadrine, aspirine et caféinemyorelaxantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OxazépambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OxcarbazépineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Oxybate de sodiumdépresseur du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OxycodoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Oxycodone et paracétamolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • OxymorphoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PalipéridoneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Paracétamol et codéineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Pentazocine et naloxoneopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PérampanelanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PerphénazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PéthidineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PhénobarbitalbarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Phénobarbital, hyoscyamine, atropine et scopolaminebarbituriqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Phentermine et topiramatestimulant du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PhénytoïneanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PimozideantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Pramipexoleagoniste de la dopamineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PrégabalineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • PrimidoneanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ProchlorpérazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ProméthazineantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Prométhazine et codéineopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Prométhazine et dextrométhorphaneantihistaminiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Propofoldépresseur du SNCMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Protriptylineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • QuétiapineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Rameltéonsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • RémifentanilopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • RispéridoneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Ropiniroleagoniste de la dopamineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • RufinamideanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ScopolamineanticholinergiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Sévofluraneanesthésique généralMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Suvorexantsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TapentadolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Tasimeltéonsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TémazépambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Tétrabénazineinhibiteur de VMAT2Mineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ThioridazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TiagabineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TiotixèneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TopiramateanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TramadolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Tramadol et paracétamolopioïdeMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TrazodoneantidépresseurMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TriazolambenzodiazépineMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • TrifluopérazineantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Trimipramineantidépresseur tricycliqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • VigabatrineanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Zaléplonesédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ZiprasidoneantipsychotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • Zolpidemsédatif-hypnotiqueMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

  • ZonisamideanticonvulsivantMineure

    The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

Vérifiez Époétine alfa avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.